The QualityStocks Daily Wednesday, June 26th, 2024

Today's Top 3 Investment Newsletters

QualityStocks(AGRX) $1.4400 +331.14%

360 Wall Street(WENA) $3.6200 +119.39%

Premium Stock Alerts(FFIE) $0.4585 +73.02%

The QualityStocks Daily Stock List

Agile Therapeutics (AGRX)

MarketBeat, QualityStocks, StreetInsider, StockMarketWatch, MarketClub Analysis,, TradersPro, Kiplinger Today, Barchart, The Street, StockEarnings, TraderPower, StocksEarning, BUYINS.NET, OTCtipReporter, AllPennyStocks, Money and Markets, PennyStockScholar, PoliticsAndMyPortfolio, 360 Wall Street, Stock Beast, Zacks, Street Insider, The Online Investor, TopPennyStockMovers, Wealth Insider Alert and Profitable Trader Authority reported earlier on Agile Therapeutics (AGRX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Agile Therapeutics Inc. (NASDAQ: AGRX) (FRA: 0AL) is a pharmaceutical firm that is engaged in research, developing and commercializing prescription contraceptive products for women in the U.S.

Agile Therapeutics Inc. is based in Princeton, New Jersey and was founded on December 22, 1997 by Chien Te Yen. The firm develops a pipeline of investigational contraceptive products in the U.S.

Agile Therapeutics Inc.’s product candidates include a low-dose, combined hormonal contraceptive patch known as AG200-15 or Twirla. The contraceptive patch contains ethinyl estradiol and levonorgestrel, which are the active ingredients. Apart from this, the firm also develops other transdermal contraceptive products, including a regimen the firm developed to allow women to have 4 episodes of withdrawal bleeding annually known as AG200-ER; a regimen developed to offer women a shortened hormone-free interval as well as extend the length of her contraceptive cycle dubbed AG200-15 ER SP and a progestin-only contraceptive patch that was designed for women who are unwilling or unable to take estrogen known as AG890. Each of the firm’s product candidates uses its Skinfusion technology, which has been designed to convey contraceptive levels of hormones to an individual’s bloodstream through their skin, over a one-week period.

Agile Therapeutics Inc. recently launched their drug candidate Twirla on the U.S. market as an effective modern contraceptive option for women. The drug’s accessibility, affordability and administration technique makes it a good option to choose from the many other contraceptives on the market. Additionally, the fact that it is safe, reliable, decreases the burden of daily administration and requires no invasive procedures makes it the best solution for women who need a birth control product that fits into their active lifestyle.

Agile Therapeutics (AGRX), closed Wednesday's trading session at $1.44, up 331.1377%, on 4,906,490 volume with 00 trades. The average volume for the last 3 months is 9.215M and the stock's 52-week low/high is $0.20 /$3.40 .

Ocean Power Technologies (OPTT), QualityStocks, SmarTrend Newsletters, InvestorPlace, StreetInsider, MarketClub Analysis, StockMarketWatch, BUYINS.NET, MarketBeat, Jason Bond, TraderPower, Wall Street Grand, TheStockAdvisor, OTCtipReporter, PennyStockScholar, The Street, Schaeffer's, National Inflation Association, Alternative Energy, Bull in Advantage, FeedBlitz, GreatStockPix, The Online Investor, Stock Stars, Money Morning, Stock Market Watch, StockOodles, The Best Newsletters, TradersPro, Investing Futures, Investor Ideas, Dynamic Wealth Report, DreamTeamNetwork, Cabot Wealth, Barchart, AnotherWinningTrade, Market FN,, Stock Beast, Wall Street Greek, Trading Concepts, Trades Of The Day, TopStockAnalysts, TopPennyStockMovers, StocksEarning, PennyToBuck, Stock Research Newsletter,, SmallCapVoice, Real Pennies, Wall Street Mover, Promotion Stock Secrets, OTCPicks, MarketDeal and StockEarnings reported earlier on Ocean Power Technologies (OPTT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ocean Power Technologies Inc. (NASDAQ: OPTT) (FRA: RUOC) is focused on the development and commercialization of proprietary systems which generate electricity from the renewable energy of ocean waves in Asia, Europe, South and North America.

Ocean Power Technologies is based in Monroe Township, New Jersey and was incorporated on April 19, 1984 by George W. Taylor. The firm serves agencies as well as private and public entities that need remote offshore power. The majority of the firm’s revenue is generated from North America.

Ocean Power Technologies operates in the following geographical segments: Australia, Asia, Europe and North America. The firm is focused on developing its PowerBuoy product line, which is based on ocean-going modular buoys, for use in autonomous power applications. The PowerBuoy system integrates patented technologies in energy conversion, electronic, hydrodynamics and computer control systems to obtain natural energy from the waves of the ocean.

Ocean Power Technologies offers marine installation services, integration services and payloads as well as various hybrid PowerBuoy products such as subsea battery systems. Additionally, the firm also provides real-time data communications and electric power for subsea applications and remote offshore markets such as communications, science and research, defense and security and offshore oil and gas.

As of 2021, Ocean Power Technologies had acquired 3Dent Technology, an energy engineering firm, which will broaden Ocean Power’s ability to offer comprehensive solutions to consumers, which will accelerate the growth of both firms and also expand and solidify Ocean Power’s position as an offshore energy solution provider.

Ocean Power Technologies (OPTT), closed Wednesday's trading session at $0.1812, up 34.9218%, on 403,537,168 volume with 00 trades. The average volume for the last 3 months is 71,964 and the stock's 52-week low/high is $0.12 /$0.769 .

NervGen Pharma Corp. (NGENF)

QualityStocks, TradersPro, MarketBeat and AllPennyStocks reported earlier on NervGen Pharma Corp. (NGENF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NervGen Pharma Corp. is a regenerative medicine company listed on the OTC Markets Group’s OTCQX. The Company’s commitment is to creating leading-edge solutions for the treatment of nerve damage. This includes spinal cord and peripheral nerve injury. The Company’s lead compound is NVG-291. NervGen Pharma has its corporate headquarters in Vancouver, British Columbia.

NervGen’s core technology targets protein tyrosine phosphatase sigma (PTPσ). This is a neural receptor that impedes nerve regeneration. Inhibition of the PTPσ receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for diverse medical conditions. Research has been conducted on other applications of PTPs including MS, stroke, cardiac arrhythmia, and Alzheimer’s Disease.

In addition, the Company continues to research secondary applications including multiple sclerosis, acute myocardial infarction induced arrhythmia (AMI, normally known as a heart attack), stroke and other neurodegenerative diseases. NervGen’s plan is to begin a Phase 1 human clinical trial for its lead compound, NVG-291, in early 2020 under an Investigational New Drug application with the US Food and Drug Administration (FDA).

NervGen Pharma is advancing NVG-291 for the treatment of spinal cord injury as it believes this indication is a significant opportunity due to the present lack of non-surgical solutions in the market, the considerable impact on quality of life, and the high cost burden to the healthcare system. The Company’s belief is that NVG-291 as a therapy could alleviate or improve upon the symptoms and conditions associated with spinal cord injury. It also believes that NVG-291 as a therapy could empower these patients to live more active and productive lives.

NervGen Pharma Corp. (NGENF), closed Wednesday's trading session at $2.1, up 14.7541%, on 142,089 volume with 00 trades. The average volume for the last 3 months is 149,516 and the stock's 52-week low/high is $1.16 /$2.99 .

GCM Grosvenor (GCMG)

MarketBeat, DividendStocks, InsiderTrades, Zacks, TradersPro and MarketClub Analysis reported earlier on GCM Grosvenor (GCMG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GCM Grosvenor Inc. (NASDAQ: GCMG) (NASDAQ: GCMGW) is an international alternative asset management solutions provider.

The firm has its headquarters in Chicago, Illinois and was incorporated in 1971. It operates as part of the asset management industry, under the financial services sector. The firm serves consumers around the globe.

The company has specialized in alternatives for more than five decades and focuses on Ohio and the Midwest region. It employs fundamental and quantitative analysis in its activities and has additional offices in Asia, North America, Europe and Australia.

The enterprise primarily offers its services to pooled investment vehicles. It also offers its services to high net worth individuals, investment firms, pension and profit-sharing plans and state or municipal government entities. The enterprise invests in equity and alternative investment markets of the United States and internationally. It also invests in multi-strategy, equity-focused, credit-focused, macro-focused, commodity-focused, and other specialty portfolios. It focuses on hedge fund asset classes, real estate, private equity, and/or infrastructure, credit and absolute return strategies. In addition to this, the enterprise focuses on secondary fund investments, primary fund investments, and co-investments with a focus on buyout, distressed debt, mezzanine, venture capital/growth equity investments. The enterprise seeks to do seed investments in small, emerging, and diverse private equity firms. It also seeks to make regionally-focused investments in middle-market buyouts. The enterprise prefers to invest in aerospace and defense, advanced electronics, information technology, biosciences, and advanced materials.

The firm, which recently released its latest financial results, remains committed to creating additional value for its shareholders.

GCM Grosvenor (GCMG), closed Wednesday's trading session at $9.62, up -0.5170631%, on 72,601 volume with 00 trades. The average volume for the last 3 months is 5.578M and the stock's 52-week low/high is $7.24 /$10.20 . Inc. (AI)

Schaeffer's, InvestorPlace, The Online Investor, Marketbeat, INO Market Report, MarketClub Analysis, Early Bird,, StreetInsider, The Street, Investopedia, Zacks, QualityStocks, The Wealth Report, InvestorsUnderground, Daily Trade Alert, FreeRealTime, Street Insider, The Street Report, Investment House, StrategicTechInvestor, StreetAuthority Daily, DividendStocks, Total Wealth, Cabot Wealth, Trades Of The Day, AllPennyStocks, 360 Wall Street, Eagle Financial Publications, Hit and Run Candle Sticks, Dividend Opportunities, CNBC Breaking News, InsiderTrades, Investiv, Prism MarketView, Wall Street Greek, Wall St. Warrior, TradersPro, TipRanks, Timothy Sykes, Tim Bohen, The Night Owl, MicrocapAlliance, Stansberry Research, Investors Alley, OilAndEnergyInvestor, Money Wealth Matters, Money and Markets, 247 Market News, Louis Navellier, Liberty Through Wealth, Kiplinger Today and StockMarketWatch reported earlier on Inc. (AI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Last week, the U.S. Department of Treasury issued a proposal that would limit and monitor United States investments in China for a range of tech investments. The proposal stems from an executive order issued by President Joseph Biden in 2023 that focused on access that some countries had to U.S. dollars to finance advanced technologies that could strengthen these countries’ intelligence, military, cyber capabilities and surveillance. The order primarily centered on Macau, Hong Kong and China.

For a while now, the current administration has worked to impede the development of technologies that could enable China to dominate emerging sectors or give it a military edge. The United States even imposed a tariff on electric vehicles, solar cells, batteries, aluminum, steel and medical equipment from China. This move has political implications for President Biden and former president Donald Trump, who are both trying to demonstrate to the public who can best stand up to the east Asian nation.

Currently, the People’s Republic of China is the second-largest economy globally. The country is also a major trading partner and geopolitical rival of the United States.

The recent proposal touches on data that permanent residents of the United States as well as the country’s citizens must provide when participating in transactions with this country. It also discusses actions that would be considered as violations.

Specifically, the rule would ban investors in the U.S. from funding artificial-intelligence systems in China that could be used for military applications such as location tracking, combat and weapons targeting.

The treasury is currently open to comments on the proposed rule until the start of August 2024. Once this period lapses, the department is expected to issue a final regulation.

While officials in the Biden administration have insisted that they are not interested in severing relations with China, tensions between both countries have increased in the last couple of years. Last year, the United States military shot down a spy balloon suspected to be Chinese off the East Coast after the balloon passed over sensitive military sites. This action led China to threaten retaliation.

Since then, various incidents between the two countries involving national security concerns have occurred almost on a regular basis. For example, Biden gave an order in May 2024 to prevent a cryptocurrency mining company backed by Chinese investors from owning land near a nuclear missile base in Wyoming. In his order, the president noted that proximity to this area was a national security risk.

These proposed curbs could redirect the investments that would have gone to Chinese AI and tech companies to domestic companies such as Inc. (NYSE: AI) so that they are better able to ramp up their innovation solutions in this rapidly growing industry. Inc. (AI), closed Wednesday's trading session at $27.64, up 0.6188569%, on 2,832,383 volume with 00 trades. The average volume for the last 3 months is 324,550 and the stock's 52-week low/high is $20.23 /$44.90 .

TerrAscend Corp. (TSNDF)

QualityStocks, InvestorPlace, CannabisNewsWire and Cabot Wealth reported earlier on TerrAscend Corp. (TSNDF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Last week, the senate in the state of North Carolina voted to approve the legalization of medical cannabis in an initial vote. Thirty-three legislators voted in favor of the proposal, including nine Republican Party members. This move comes after legislators in the state included medical cannabis in a proposal that was originally meant to regulate hemp. The updated proposal would legalize marijuana for individuals with debilitating medical conditions.

However, before it can be advanced to the house, it must be approved by the senate a second time.

In the past, GOP party members have hindered access to legal medical marijuana. For instance, Republican legislators failed to approved a measure that would have legalized the use of medical marijuana for use by patients with eligible conditions in 2023.

The second vote has been scheduled for this week.

Senator Danny Britt, who is responsible for medical cannabis’ inclusion in the proposal, stated that getting ahead of cannabis’ possible rescheduling by the federal government was necessary. This comes after the Biden Administration proposed that cannabis be downgraded to a Schedule 3 substance in May.

The public commentary period has already began and will continue until mid-July. Currently, cannabis is classified under Schedule 1 of the Controlled Substances Act, together with other drugs, including heroin, LSD, mescaline, psilocybin and MDMA, among others. Drugs under this classification are said to have a high potential for abuse and no accepted medical use.

In the meantime, the house in North Carolina may make amendments to the proposal or reject the entire bill.

When asked about the proposal’s chances of approval, House Speaker Tim Moore gave no definite answer. Instead, he stated that he believed legislators in the house would privately discuss the proposal in the coming week. In the past, Moore has shown that he is open to medical cannabis but hasn’t brought the issue to a vote because most of his GOP colleagues oppose the idea.

This proposal comes as a Native American tribe, which is the sole seller of medical marijuana in the state, prepares to launch recreational sales for individuals aged 21 years of age and older. The tribal council of the Eastern Band of Cherokee Indians recently voted to amend a code that would permit the sale of recreational marijuana, which would make the substance legal in its Qualla Boundary.

The code in question, Ordinance 63, was amended in an 8-to-2 vote. The tribe launched medical cannabis sales in April of this year.

Major marijuana companies such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) will be following the developments in North Carolina to see if it becomes the next state to end marijuana prohibition.

TerrAscend Corp. (TSNDF), closed Wednesday's trading session at $1.5, up 4.7998%, on 417,129 volume with 00 trades. The average volume for the last 3 months is 41.354M and the stock's 52-week low/high is $1.29 /$2.45 .

Rivian Automotive Inc. (RIVN)

InvestorPlace, Schaeffer's, QualityStocks, The Street, Kiplinger Today, MarketBeat, MarketClub Analysis, Early Bird, INO Market Report, StockEarnings, Investopedia, The Online Investor, Zacks, GreenCarStocks, Daily Trade Alert, AllPennyStocks, Trades Of The Day, StocksEarning, The Night Owl, TipRanks, Louis Navellier, BillionDollarClub, DividendStocks, InvestorIntel, InvestorsUnderground, FreeRealTime, Cabot Wealth, Hit and Run Candle Sticks, 360 Wall Street, bullseyeoptiontrading, Top Pros' Top Picks, Top Pros’ Top Picks and Investors Underground reported earlier on Rivian Automotive Inc. (RIVN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Research from a Washington-based think tank has revealed that China invested at least $230 billion into its electric-vehicle industry to “flood the market” with more affordable Chinese-made battery electric vehicles (BEV). The analysis is in line with the European Commission’s sentiment on the effect of Beijing’s subsidies on the global BEV industry. Furthermore, the Center for Strategic and International Studies (CSIS) notes that this figure is a “highly conservative estimate” of the funds China has pumped into its EV sector.

The east Asian nation’s investment in electric cars dwarfs anything any other country has spent on new energy vehicles over the past decade. As a result, China is home to a massive electric vehicle industry with 200 EV producers jostling for supremacy. With the sector producing much more than the domestic buyers can reasonably consume, China began exporting EVs en masse to the European market before EU leaders launched an investigation into Beijing’s EV subsidies.

Thanks to the decade-long cash infusion from Beijing, China’s auto sector is poised to reach 10 million in electric vehicle sales this year, making it the largest EV market on the globe ahead of both the United States and Europe. CSIS’s research says the Chinese government pumped $230.8 billion into its EV industry from 2009 to 2023, at an average of around $6.74 billion per year for the first nine years. The funding then tripled over the next three years before spiking even further in 2021.

The think tank’s research was based on five key areas: government EV purchases, national rebate programs, exemption from the country’s 10% sales tax, development programs for electric vehicle manufacturers and government funding for beneficial infrastructure. The sales tax coupled with the buyers’ rebate, which lasted until 2023, constituted most of the Chinese government’s support.

The Center for Strategic and International Studies believes these estimates are on the low end because they don’t account for factors such as rebate programs run by local governments or the provision of low-cost electricity, credit and land to electric-vehicle companies. In addition, its analysis didn’t include subsidies for other areas of the auto supply chain, such as mining and processing EV raw materials as well as the development of electric vehicle batteries.

As such, EV battery giant CATL, which received a whopping $809.2 million in subsidies last year alone, didn’t affect the research findings. Unfortunately, Chinese EV makers may be unable to leverage their affordability to gain a foothold in major foreign markets. The U.S. has already started levying a 100% tariff on Chinese EVs, and the EU is also set to levy provisional tariffs.

Other countries are also supporting their domestic EV industries, and companies such as Rivian Automotive Inc. (NASDAQ: RIVN) may be reaping the benefits of some of those initiatives, includes sales incentives and rebates.

Rivian Automotive Inc. (RIVN), closed Wednesday's trading session at $14.74, up 23.2441%, on 261,980,425 volume with 00 trades. The average volume for the last 3 months is 8.903M and the stock's 52-week low/high is $8.26 /$28.06 .

Coinbase Global Inc. (COIN)

Schaeffer's, InvestorPlace, The Street, QualityStocks, MarketClub Analysis, Prfmonline, Zacks, MarketBeat, Greenbackers, Early Bird, StockEarnings, Kiplinger Today, INO Market Report, Investopedia, OTCPicks, SmallCapVoice, The Online Investor, Ceocast News, The Wealth Report, InsiderTrades, HotOTC, CoolPennyStocks, Daily Trade Alert, Trades Of The Day, StocksEarning, StockEgg, Penny Invest, Stock Stars, TradersPro, Stock Rich, CryptoCurrencyWire, FreeRealTime, Top Pros' Top Picks, BestOtc, The Stock Psycho, Top Gun, CNBC Breaking News, BullRally, HotShotStocks, BillionDollarClub, Investors Underground, Wealth Daily, StockHotTips, bullseyeoptiontrading, FeedBlitz, Jeff Bishop, Today's Financial News, MadPennyStocks, Energy and Capital, Smartmoneytrading, Summa Money, StockRich, PennyInvest, PennyStockVille, PennyTrader Publisher, Cabot Wealth, Stockpalooza, Profit Confidential, WiseAlerts, DividendStocks, AlphaShark Trading, Atomic Trades, Dawn Report, wealthmintrplus, CRWEWallStreet, BloomMoney, wyatt research newsletter, Dynamic Wealth Report, Blaque Capital Stocks, Stock Fortune Teller, InvestorsUnderground, Round Up the Bulls, StockMister, Pennybuster, Penny Stock Rumble, AllPennyStocks, Momentum Traders, MicrocapVoice, TradingPub, Louis Navellier, Eagle Financial Publications, Standout Stocks, Penny Stock Finder, Stock Traders Chat, Trading with Larry Benedict, Green Chip Stocks, Stock Analyzer, Early Investing, Wealth Whisperer and TipRanks reported earlier on Coinbase Global Inc. (COIN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A few days ago, Coinbase Global Inc. (NASDAQ: COIN), the leading cryptocurrency exchange platform, suffered a significant downturn compared to the general market. As the week’s trading session ended las week, the cryptocurrency exchange had an ending of $235.03, signifying a 0.39% decrease. This drop has raised several eyebrows, with investors and analysts asking serious questions about Coinbase’s prospects.

Founded in 2012, Coinbase Global provides a secure environment for people to buy, sell and store various cryptocurrencies, thus playing a critical role in the rapidly expanding digital asset market. Since it was one of the major cryptocurrency companies that went public less than five years ago, Coinbase has played a significant role in determining the future of the industry and investors’ sentiment toward crypto assets.

The company’s market capitalization is at $54.72 billion, with outstanding shares of 245.57 million, signifying a substantial market gap. This places Coinbase among the larger crypto entities in the market, showing its significant role in the industry.

The overall crypto market experienced volatility, which was influenced by various factors, one of them being regulatory concerns. There is ongoing regulatory scrutiny by policymakers who recently gathered for the spring meetings and highlighted the need for crypto-asset regulations. These regulatory concerns have resulted in investors’ concerns about investing in these assets.

Additionally, earnings reports and future projections are playing a significant role in Coinbase stock performance. If there is any hint of missed revenue targets or one that is lower than expected, it could lead to a decline in stock value. Crypto investors always keep an eye on these reports to determine the growth prospects of the company.

Furthermore, a drop in Coinbase’s stock could be due to market sentiment. Market sentiments refer to people’s attitudes, opinions and emotions toward cryptocurrency. The broader market sentiments toward digital assets could significantly influence investor decisions toward cryptos.

Similarly, with the emergence of new cryptocurrency exchange platforms, it is becoming more difficult for Coinbase to compete with emerging platforms that are offering lower fees and innovative services. These enticing deals offered by new market entrants are attractive to Coinbase’s user base, thus impacting its market share and stock value.

However, Coinbase Global is not alone. The general market has faced challenges that include economic uncertainty, interest rate changes and geopolitical tensions, which have led to broader market declines that have significantly influenced individual stocks. However, analysts believe that the sharp decline in Coinbase stock signifies a much deeper issue involving the crypto exchange market and regulatory environment.

Coinbase Global Inc. (COIN), closed Wednesday's trading session at $214.58, up -3.2159%, on 6,574,922 volume with 00 trades. The average volume for the last 3 months is 2.979M and the stock's 52-week low/high is $61.00 /$283.48 .

HIVE Blockchain Technologies Ltd. (HIVE)

QualityStocks, InvestorPlace, MarketClub Analysis, MarketBeat, CryptoCurrencyWire, Zacks, StreetInsider, Early Bird,, StockMarketWatch, Stock Market Watch, Greenbackers, Hit and Run Candle Sticks, Barchart, smartOTC, StockOodles, StreetAuthority Daily, The Night Owl, The Online Investor, TopStockAnalysts, Wall Street Resources, WealthMakers and Schaeffer's reported earlier on HIVE Blockchain Technologies Ltd. (HIVE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

StanChart is set to launch a spot crypto trading platform for Ethereum and Bitcoin, according to sources cited by Bloomberg. The multinational financial institution intends to launch a spot crypto trading desk that will oversee Ethereum (ETH) and Bitcoin (BTC) transactions.

The move is anticipated to serve the growing number of institutional clients that are interested in Ether and Bitcoin, and will function under the bank’s foreign exchange (FX) unit. StanChart mentioned in an email to Bloomberg that it has been collaborating closely with regulators to meet the demands of institutional clients for trading Ethereum and Bitcoin.

The action aligns with the bank’s broader strategy to assist clients throughout the digital asset environment, covering aspects such as interoperability, access, custody and tokenization.

The U.S. Securities and Exchange Commission (SEC) approved two crypto spot ETFs recently, which is a major step forward for the entire sector. The SEC initially approved Bitcoin spot ETFs, leading to a notable surge in BTC’s price, which soared to a peak of $73,000 following the approval. Standard Chartered highlighted that there has been an increasing demand from its clients for these cryptocurrencies.

Cryptocentric companies such as Coinbase, Ripple and Kraken already provide custody services to institutional customers for major cryptocurrencies. Other banks, including HSBC, have hinted at plans to introduce a tokenized securities cryptocurrency custody platform in an effort to take a bigger chunk of the market.

However, strict regulations have often hindered direct engagement with underlying digital assets. For instance, issues with profitability have arisen from regulatory challenges, such as the suggestion by the Basel Committee on Banking Supervision to assign a risk rating of 1,250% for unhedged cryptocurrency exposure.

Nonetheless, StanChart has been involved in crypto investments for quite some time. The bank is a significant supporter of Zodia Custody, a crypto-asset custodian, and Zodia Markets, its exchange subsidiary. Additionally, it launched Libeara, a tokenization platform, in November 2023. The platform was designed to tokenize government bond funds utilizing the Singaporean dollar and has developed into a cornerstone of the bank’s Web3 initiatives.

StanChart stated in a February 2024 blog post that it believes stablecoins will play a significant role in financial services’ future and that digital assets will be a long-lasting part of that future. The bank’s market strategists also recently forecast that, should Trump win the U.S. presidential election, Bitcoin might rise to $150,000 by 2025. Moreover, it correctly predicted that Ethereum spot ETFs would be approved by the SEC.

Industry players such as HIVE Blockchain Technologies Ltd. (NASDAQ: HIVE) (TSX.V: HIVE) could be happy that major financial institutions including StanChart are becoming more involved in the crypto space since this conveys a message that the industry has hit mainstream.

HIVE Blockchain Technologies Ltd. (HIVE), closed Wednesday's trading session at $3.29, up 10.0334%, on 8,087,659 volume with 00 trades. The average volume for the last 3 months is 831,398 and the stock's 52-week low/high is $2.18 /$6.84 .

Curaleaf Holdings Inc. (CURLF)

InvestorPlace, QualityStocks, Kiplinger Today, MarketBeat, Cabot Wealth, Daily Trade Alert, Top Pros' Top Picks, The Online Investor, MarketClub Analysis, Profit Trends, Wealth Insider Alert, StreetInsider, Early Bird, Trading For Keeps, Trades Of The Day, The Street, Prism MarketView, TradersPro, Zacks, Schaeffer's, Investment U, StreetAuthority Daily, wyatt research newsletter, Daily Profit, CFN Media Group, CannabisNewsWire and Wyatt Investment Research reported earlier on Curaleaf Holdings Inc. (CURLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Representatives of the prohibitionist organization Smart Approaches to Marijuana (SAM) have expressed their disapproval of the government’s plan to categorize cannabis as a Schedule 3 substance. They criticized the move as politically driven and not based on scientific evidence. The group is now exploring all legal avenues to challenge this change and is rallying its supporters to oppose it.

Kevin Sabet, SAM president and CEO, spoke during an online meeting, expressing strong disapproval of the federal officials behind the rescheduling proposal. He argued that the recommendation seemed outdated and inappropriate for 2024. Sabet emphasized that the process is far from over and that a lot of actions can be taken against the proposed change.

The organization’s executive vice president, Luke Niforatos, encouraged opponents of the reform to contact policymakers and voice their concerns. He suggested that the U.S. Drug Enforcement Agency (DEA) had already indicated ways for advocates to push back against the recommendation.

SAM has been disseminating allegations that DEA officials might be against the proposed adjustment ever since the government unveiled its rescheduling proposal in April. Sabet mentioned hearing that DEA director Anne Milgram had not signed off on the proposal, suggesting internal disagreement. Instead, U.S. attorney general Merrick Garland signed the proposed rule, raising further questions during a congressional hearing, where Milgram declined to comment on the matter.

During the SAM event, Sabet acknowledged that substances with proven medical use shouldn’t be in Schedule 1, the most restrictive category of the CSA. However, he criticized the review process by the U.S. Department of Health and Human Services (HHS), which concluded cannabis has proven medical uses. He argued that the process seemed to approve substances based on popularity rather than scientific merit.

Many of the ramifications of officially classifying marijuana as Schedule 3 are still unknown, according to Sabet. One potential change is that state-licensed cannabis businesses could claim tax deductions, which might lead to the industry’s expansion. He and other panelists warned that this could result in increased marijuana use, more access for teenagers and greater risks on the roads. Sabet also downplayed the idea that rescheduling would significantly ease restrictions on marijuana research.

Looking ahead, SAM hopes the DEA might reject the recommendation or consider moving cannabis to Schedule 2. Sabet referenced international law interpretations that seem to require keeping marijuana in Schedule 1 or 2. In 2016, the DEA denied an earlier petition to reschedule cannabis, citing international treaty obligations.

Sabet expressed doubt that rescheduling would prompt the FDA to interfere with state-licensed marijuana markets. However, Niforatos urged followers to press the federal government to utilize postponement as justification for taking action against legally operating states.

The recommendation to reschedule cannabis was officially proposed last month, initiating a public comment period expected to generate diverse responses. Cannabis reform advocates plan to leverage this opportunity, with some supporting reclassification and others pushing for complete descheduling. SAM and other prohibitionists, meanwhile, are expected to continue opposing the policy change via lobbying and potential litigation.

Marijuana companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) may have expected this pushback against the rescheduling of cannabis at the federal level, and they will be following the process as it unfolds now that the authorities have opened a comment period regarding the proposed policy change.

Curaleaf Holdings Inc. (CURLF), closed Wednesday's trading session at $4.08, up 2.3839%, on 416,942 volume with 00 trades. The average volume for the last 3 months is 702,061 and the stock's 52-week low/high is $2.51 /$6.40 .

Tivic Health Systems (TIVC)

QualityStocks, Money Wealth Matters and Broad Street reported earlier on Tivic Health Systems (TIVC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tivic Health(R) Systems (NASDAQ: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of Christina Valauri to the company’s board of directors, effective July 1, 2024. “Over the past year, as an advisor to our Board and the company, Christina Valauri has demonstrated deep commitment to excellence and the highest standards of ethical governance. This, paired with her insight into capital markets and deep background in research analysis, is a powerful combination to help ensure we make the best decisions for the company, our customers and our shareholders,” TIVC Chair of the Board Sheryle Bolton stated in the news release.

To view the full press release, visit

About Tivic Health

Tivic Health is a commercial health tech company advancing the field of bioelectronic medicine. Tivic Health’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic Health’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health’s first commercial product ClearUP is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information, visit the company’s website at

Tivic Health Systems (TIVC), closed Wednesday's trading session at $0.4, up 0.5025126%, on 117,849 volume with 00 trades. The average volume for the last 3 months is 1,440 and the stock's 52-week low/high is $0.3485 /$21.75 .

GRN Holding Corp. (GRNF)

We reported earlier on GRN Holding Corp. (GRNF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GRN Holding (OTC: GRNF), a publicly quoted company focused on the global distribution and sale of marijuana in jurisdictions where it is legal, is in the process of a strategic rebranding initiative; the company is rebranding to Marijuana Inc. According to the announcement, the rebranding strategy represents “a new era of growth and innovation in the global cannabis industry.” This transformation is being led by Donald Steinberg, who has been involved in the marijuana space for more than 50 years and has been called the “Henry Ford of the marijuana industry.” Steinberg’s contributions to the world of marijuana have been well documented. Highlights of his career include being recognized by Centac, a U.S. government agency, as the largest importer of marijuana into the United States in the 1970s and the largest U.S. distributor; being interviewed by American journalist and talk show host Charlie Rose; cofounding One World Communications, one of the world’s largest affiliate marketing companies in the international telecom industry, with more than 200,000 members in 30-plus countries; and cofounding Medical Marijuana Inc., the first company on a U.S. stock exchange dedicated to the marijuana industry. With Steinberg at the helm, Marijuana Inc. is focused on revolutionizing the marijuana industry by leveraging his extensive experience, innovative vision and strategic global partnerships. “As many countries relax their laws on marijuana, I see an opportunity to be involved at the beginning of a new chapter in the marijuana industry,” said Marijuana Inc. founder Donald Steinberg in the press release. “Moving ahead with this idea, I formed Marijuana Inc., took control of an existing public company and merged the two entities to pursue growth opportunities. The name change has been filed, and we are awaiting final approval from OTC now.”

To view the full press release, visit

About GRN Holding Corporation

GRN Holding Corporation is a publicly quoted company focused on the global distribution and sale of marijuana in jurisdictions where it is legal. The company collaborates with marijuana farmers to distribute high-grade, affordable marijuana to legal consumers, wholesalers and retailers. With a team of seasoned professionals experienced in the publicly traded marijuana space, GRN Holding Corporation is committed to driving industry innovation and growth. Marijuana Inc. was founded by Donald Steinberg and is dedicated to providing high-quality cannabis products at competitive prices. The company focuses on controlling the quality of seeds, growing practices, distribution and delivery to consumers. Through its branded and curated heirloom collections, Marijuana Inc. aims to offer unique strains that stand out in the market, ensuring quality, variety and fair pricing. For more information about the company, please visit

GRN Holding Corp. (GRNF), closed Wednesday's trading session at $0.041, up 9.9196%, on 1,160 volume with 00 trades. The average volume for the last 3 months is 531,651 and the stock's 52-week low/high is $0.0311 /$0.40 .

The QualityStocks Company Corner

Annovis Bio Inc. (NYSE: ANVS)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (NYSE: ANVS).

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease ("AD") and Parkinson's disease ("PD"), has filed a patent with the U.S. Patent and Trademark Office. The patent covers novel solid forms of buntanetap, selecting the best crystal and building upon the provisional patent the company filed in June 2023. Formerly known as posiphen or ANVS401, buntanetap targets neurodegeneration by hindering the formation of multiple neurotoxic proteins connected with disease, including amyloid beta, tau, alpha-synuclein and TDP43. Through this process, buntanetap has the potential to reverse neurodegeneration in Alzheimer's, Parkinson's and other neurodegenerative diseases. The company has selected the most stable crystal form of buntanetap as the lead compound for animal bridge studies and for developing a manufacturing process. "The invention of a new solid form of our drug, buntanetap and the subsequent patent filing represent groundbreaking milestones for our company," said Annovis Bio founder, president and CEO Maria Maccecchini, PhD, in the press release. "This achievement will allow us not only to continue advancing our pipeline but also to enhance the drug's properties, ultimately providing greater benefits to our patients."

To view the full press release, visit

Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach aims to treat memory loss and dementia associated with AD and body and brain dysfunction associated with PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, Buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, Buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a -3.3 point improvement compared to -0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating Buntanetap’s mechanism of action.

Similarly, in the Phase III study of Buntanetap in patients with early Parkinson’s disease, significant advancements were observed. Topline data results are anticipated in June 2024. Preliminary findings indicate promising results in improving cognitive and motor function, underscoring Buntanetap’s potential as a transformative therapy for Parkinson’s disease.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (AD), a figure projected to rise to almost 13 million by 2050 (Alzheimer’s Association) (Republican Policy Committee). Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease (SingleCare).

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

  • Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients.
  • Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients.
  • Groundbreaking Clinical Insights: Preliminary results from Phase II studies indicate significant improvements in motor functions and speed in patients with Parkinson’s Disease (PD).
  • Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate Buntanetap’s disease-modifying potential.
  • Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s.

Management Team

Maria L. Maccecchini, Ph.D., Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.

Cheng Fang, Ph.D., Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.

Michael Christie, Ph.D., VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.

Melissa Gaines, Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.

Learn more about the Annovis Bio team on LinkedIn.

Annovis Bio Inc. (NYSE: ANVS), closed Wednesday's trading session at $5.73, up 3.0576%, on 140,491 volume with 00 trades. The average volume for the last 3 months is 549,257 and the stock's 52-week low/high is $4.79 /$22.49 .

Recent News

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

The QualityStocks Daily Newsletter would like to spotlight Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

New research has determined that the global effect of the coronavirus pandemic observed over the last four years has led to a heightened surge of other infectious illnesses. The research was conducted by Airfinity, a data and analytics company based in the United Kingdom, which is focused on monitoring and predicting trends in global public health and disease. This observation suggests that measures imposed by governments globally allowed SARS-CoV-2 to proliferate and infect millions created conditions for even more damage to be done. For its research, the company conducted an analysis which determined that globally, there had been a resurgence of at least 13 infectious illnesses, with cases reported being higher than those recorded prior to the pandemic in a number of regions. The analysis also found that more than 40 nations or territories had reported cases of at least one infectious illness increasing to levels higher than prepandemic baselines. Experts in the field argue that the only effective way to fight the coronavirus and other disease-causing pathogens, be it rare or common, is to test more individuals, track identified cases and isolate if need be. They also propose that N95 masks be used as well as ensuring indoor air is clean. Additionally, public health infrastructure and healthcare systems around the globe need to be funded properly so they can function as intended. The efforts being undertaken by enterprises to develop immunotherapies against various infectious diseases, such as Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), could provide viable ways to treat some of these rapidly reemerging infectious diseases.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, Scinai is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. Scinai is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, Scinai has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, Scinai signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. Scinai anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of Scinai’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

Scinai has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, Scinai will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. Scinai anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

CDMO Services

While NanoAb pipeline development is Scinai’s core focus, the company also offers its cGMP manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for contract development and manufacturing organization (CDMO) services. This offering is designed to keep the Scinai team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb pipeline development.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future Scinai drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is Scinai’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at Scinai. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at Scinai. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining Scinai, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at Scinai. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to Scinai through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), closed Wednesday's trading session at $3.2, up 3.5599%, on 38,641 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $22.49 /$.

Recent News

HealthLynked Corp. (OTCQB: HLYK)

The QualityStocks Daily Newsletter would like to spotlightFathom HealthLynked Corp. (OTCQB: HLYK) .

HealthLynked (OTCQB: HLYK), a leading provider of healthcare technology solutions, has announced a new chief operating officer. According to the announcement, the company has promoted Bill Crupi to the position, effective immediately. Crupi joined the company last year and has been instrumental in optimizing operational efficiencies and supporting the company's growth trajectory. Crupi has more than 20 years' experience working in the healthcare industry and has served in several operational management leadership roles. In his new role, Crupi will manage the daily operations of HealthLynked, with a specific focus on enhancing operational efficiencies, driving strategic initiatives and ensuring the seamless delivery of healthcare services. "We are delighted to elevate Bill Crupi to the role of chief operating officer," said HealthLynked founder and CEO Dr. Michael Dent in the press release. "Bill's extensive experience and proven track record in operational management make him the ideal candidate to lead our operations. Over the past year, I have had the pleasure of working closely with Bill and have been consistently impressed with his deep understanding of healthcare and his vision for how HealthLynked can significantly improve healthcare for everyone. His strategic insights and dedication have been invaluable to our success, and we are confident that under his leadership, HealthLynked will continue to thrive and expand."

To view the full press release, visit

HealthLynked Corp. (OTCQB: HLYK) is at the forefront of a transformative movement in healthcare, utilizing its extensive collection of health data to improve care for all. With a commitment to leveraging its advanced technology platforms, HealthLynked employs a sophisticated, cloud-based network that serves as a comprehensive repository for personal health data. This system not only simplifies the management and archiving of medical records but also enables the application of AI to deliver personalized healthcare insights. Through deep analysis of this data, HealthLynked’s AI capabilities help identify the root causes of diseases, tailor healthcare solutions to individual needs, and accelerate medical discoveries.

HealthLynked Corp. App

In addition to these capabilities, HealthLynked provides a user-friendly platform for booking healthcare appointments, similar to how OpenTable operates for restaurant reservations. This feature allows patients to conveniently book appointments with healthcare providers across the country, including options for telemedicine consultations, enhancing accessibility and efficiency in healthcare service delivery.

Strategically headquartered in Naples, Florida, HealthLynked operates through three primary divisions: Health Services, Digital Healthcare, and Medical Distribution. Each division supports the company’s mission to revolutionize patient care and health management. Positioned as a potential leader in healthcare AI, HealthLynked is dedicated to shaping the future of the industry over the next 20 years, driving significant advancements in healthcare accessibility and effectiveness through innovation and technology.

HealthLynked Corp. Reach

Strategic Initiatives and Operational Highlights

The company’s commitment to enhancing global health is evident in its dual goals: transforming healthcare through advanced technology and creating a patient-centric network that accelerates medical discoveries and the development of disease cures.

HealthLynked’s intellectual property portfolio is robust and strategically developed to enhance healthcare delivery and management. In March 2023, HealthLynked was granted a patent for a groundbreaking healthcare-specific wireless access point, known as the “Patient Access Hub.” This technology significantly improves the efficiency of healthcare practices by enabling real-time monitoring of patient flow within facilities. It intelligently determines patients waiting in exam rooms and calculates wait times, alongside other critical practice metrics. This system not only enhances patient experience by reducing unnecessary wait times but also optimizes resource allocation within healthcare settings.

Additionally, in October 2023, HealthLynked filed a patent application for its advanced AI program, ARI (Augmented Real-time Interface). ARI acts as a virtual doctor for patients, capable of performing medical intake, booking appointments, and providing personalized medical recommendations based on a patient’s medical history. By integrating these tasks, ARI streamlines the healthcare process, reducing the administrative burden on healthcare providers and ensuring that patients receive timely and tailored healthcare advice. This AI-driven interface enhances the accessibility and personalization of healthcare, embodying HealthLynked’s commitment to leveraging technology for better health outcomes. The company recently launched HealthLynked 3.2.0, an advanced version of its application, incorporating telemedicine, AI-driven personal healthcare guidance, and remote patient monitoring – setting a new standard in healthcare technology.

Market Position and Future Outlook

According to Facts and Figures Research, a research and consulting firm, the global market for patient-centric healthcare applications is projected to reach $41.6 billion by 2030, growing at a CAGR of 18.77% from 2022. HealthLynked’s offerings align perfectly with this expansive market opportunity, especially with increasing demands for digital health solutions and data management in healthcare.

HealthLynked’s strategic direction, spearheaded by its seasoned management team, is designed to leverage these market dynamics, enhancing patient engagement and healthcare efficiency on a global scale.

Management Team

Michael T. Dent, M.D., Founder, CEO, and Chairman, brings extensive experience from his foundational role at NeoGenomics and leadership in various healthcare and technology sector companies.

David Rosal, CFO, with previous senior roles at Teradata and McDonald’s Corporation, brings a wealth of expertise in financial and business integration strategies essential for growth and operational efficiency.

Chris Hall, CTO, with a strong background in global technology development from his time at Siemens and several patents to his name, is instrumental in driving the innovation and technological advancement at HealthLynked.

Bill Crupi, Operations Manager, has a proven track record in streamlining operations and enhancing productivity across multiple sectors within the healthcare industry. His expertise is crucial in maintaining the operational excellence that HealthLynked is known for.

Michael Paisan, Director of Investor Relations, leverages his extensive experience in finance and communications to enhance HealthLynked’s relationships with investors and stakeholders, ensuring transparent and effective communication of the company’s value and growth strategy.

Gagan Babber, Manager of Software Development, oversees the HealthLynked development teams based in the U.S. and India. With a robust background in engineering and software development, he plays a critical role in guiding the technological direction of HealthLynked’s products. His expertise in developing scalable, innovative software solutions is essential for driving the company’s technical initiatives forward and ensuring that HealthLynked stays at the forefront of digital healthcare technology.

HealthLynked Corp. (OTCQB: HLYK), closed Wednesday's trading session at $0.081, up 1.25%, on 56,600 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.033 /$0.0999 .

Recent News

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF)

The QualityStocks Daily Newsletter would like to spotlight First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) .

In May, the European Securities and Markets Authority announced new regulations to address confusion and contradictions on sustainable investing. This move calls attention to the debate over whether stocks from fossil-fuel companies should be included in environmental, social and governance (ESG) funds. It also tightens regulations on sustainable investing and puts more than one-half of ESG funds in Europe on notice, prompting some fuds to change their names to accurately reflect their holdings or sell off billions in assets. It is important to note that both of the above categories exclude oil, coal, high-emission electricity production and gaseous fuels. Under the new rules, managers can use the term "transition" to name their funds, as long as they meet the benchmarks. Firms excluded under this are weapon and tobacco companies, with the body noting that transition activities are ones with low-carbon alternatives that minimize emissions. For investors uncertain about the likely long-term impact of the rule changes in the EU, stocks in entities such as First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) could be a viable option for those wishing to put their investment money in entities that espouse ESG principles.

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential.

The company is headquartered in Vancouver, British Columbia.

Tellurium and the Green Energy Revolution

Tellurium has a key role to play in the ongoing green energy revolution. It is widely used in the manufacturing of photovoltaic cells for solar panels.

Despite this utility, ongoing trade tensions between China and the U.S. create implications for both tellurium and the production of cadmium-tellurium solar cells. Earlier this year, China announced plans to restrict exports of critical metals gallium and germanium, both essential for the production of semiconductors. For reference, China produces around 80% of the world’s gallium and approximately 60% of the world’s germanium.

China’s recent trade restrictions amplify the fragility of the North American tellurium supply, as the Asian nation currently produces about 60% of the world’s tellurium. This sustained supply vulnerability is why First Solar, the United States’ largest solar panel producer, set up a worldwide search for tellurium deposits in the mid-2000s.

“In North America alone, our understanding is that First Solar looked at over a hundred tellurium properties,” First Tellurium CEO Tyrone Docherty stated in a news release. “Their number one property by far, which they acquired, was the Colorado Klondike which we now control.”

The U.S. is now looking to secure safe, domestic sources of tellurium and many other critical metals to pre-empt potential shortages. The Biden administration has instituted a stream of policies, particularly the U.S. Inflation Reduction Act, to source solar components from North America and other “friendly” jurisdictions.

As the only junior mining company in the world focused on tellurium exploration, First Tellurium is ahead of the curve in capitalizing on these initiatives to establish strategic, domestic supplies of key resources for solar panel manufacturers.

First Tellurium’s ESG Initiatives

Through its exploration and partnerships with Fenix Advanced Materials, Cheona Metals and IRMA, First Tellurium strives to generate a measurable, beneficial social or environmental impact alongside a financial return. The company conducts a diversified search for metals, working in alliance with indigenous peoples, NGOs, governments and leading metals buyers. First Tellurium believes this is the future of mineral exploration — generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to, and supports, the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and, in particular, the fundamental proposition of free, prior and informed consent.



Deer Horn Tellurium-Gold-Silver-Copper Project

Deer Horn is located on 51.33 square kilometers (km) in west-central British Columbia, 36 km south of the prolific Huckleberry copper-molybdenum mine and 135 km southwest of the community of Burns Lake. It is one of few significant tellurium discoveries outside Asia and includes a 2.4 km-long vein system of high-grade gold, silver and tellurium, as well as broader zones of bulk-tonnage gold, silver and tellurium mineralization. The company completed a positive Preliminary Economic Estimate and has begun permitting for a 10,000-tonne bulk sample program to advance the project toward mine feasibility. It is North America’s only silver-gold-tellurium property with an NI 43-101 compliant tellurium resource, and it hosts a number of other mineralized targets and zone containing critical metals such as copper, tungsten and zinc.

First Tellurium owns 50% of the property, with an option to acquire up to a 75% interest. The company has engaged Dias Geophysical of Saskatoon, Saskatchewan, to conduct induced polarization (IP) geophysics on the Deer Horn Project in summer 2023. The program is designed to help develop drill targets for a subsequent drilling program.

Klondike Gold-Tellurium Project

The Klondike property is located in Saguache County, Colorado, southwest of Buena Vista in the state’s historical mining district. The company reports it has engaged Burgex Mining Consultants of Sandy, Utah, to stake additional claims around the Klondike property. The claims have been filed with the Bureau of Land Management.

Klondike demonstrates exceptional tellurium grades. Tellurium, used in high-efficiency cadmium telluride (Cd-Te) solar panels, next-generation lithium-ion batteries and thermoelectric devices to change heat into energy, is an essential element for the world’s transition to green energy.

The Klondike property was a top tellurium prospect owned previously by First Solar Inc., one of the world’s largest solar panel producers. First Solar terminated its worldwide raw materials exploration program in 2012 and sold the property to Colorado Klondike LLC, which optioned the project to First Tellurium. Colorado Klondike, led by First Solar’s former Exploration Manager in North America, is managing the upcoming exploration program.

The Colorado Geological Survey (CGS), in partnership with the Colorado School of Mines, reported on First Solar’s exploration at Klondike in 2015, noting: “Surface sampling by First Solar, Inc. in 2006 found very high tellurium grades of up to 3.3% (33,000 ppm), along with locally high gold grades. Tellurium grades at Klondike were the highest encountered in the company’s nationwide exploration program.”

Market Outlook

First Tellurium in spring 2023 referenced recent forecasts by the International Energy Agency (IEA) pointing to rapid growth in solar photovoltaic (solar PV) deployment worldwide. According to the agency, solar PV installations will generate more power by 2027 than any other energy source, including coal, natural gas and hydro. To meet this demand, consumption of both silver and tellurium, key components of solar panels, is expected to surge in coming years.

Chen Lin, founder of Lin Asset Management, has written in his investment newsletter for clients that solar PV is now the largest industrial usage of silver. He said that in 2022 solar PV production used about 12% of total silver demand, or about 120 million ounces of silver. Lin expects this number to rise dramatically in the coming years, and that is likely to lead to silver supply deficits for decades to come.

Lin points out that solar power is now the cheapest source of energy in many parts of the world and that all forecasts point to dramatic expansion of solar PV in the coming two decades. Conservative estimates forecast 300 gigawatts of solar PV production by 2027, up from the current level of about 200 gigawatts.

Management Team

Tyrone Docherty is President, Director and CEO of First Tellurium Corp. He previously served as President and CEO of Quinto Mining Inc., taking over when it had a market cap of $4 million. With limited resources in a difficult market environment, he raised more than $30 million and advanced Quinto’s Quebec iron ore property to a viable project. Quinto later sold for $175 million, with Quinto management taking shares of the purchaser, Consolidated Thompson Iron Mines, amounting to approximately 20-21% of that company. Consolidated Thompson Iron Mines sold two years later for $4.9 billion, giving the former Quinto team an enterprise value of approximately $1 billion. From 2012 to 2018, Mr. Docherty was Director and Chairman of Mason Graphite Inc. He has worked in the financial and minerals markets for more than 30 years.

Tony Fogarassy, M.Sc. LL.M., is Chairman of First Tellurium Corp. He is a lawyer and a geologist. His extensive legal and technical expertise includes minerals, oil and gas, coal and renewable energy projects and environmental and aboriginal/indigenous law in North America, Africa and Asia. He graduated as gold medalist in geological sciences from the University of British Columbia and in law from the London School of Economics.

First Tellurium Corp. (OTCQB: FSTTF), closed Wednesday's trading session at $0.068, up 1.4925%, on 9,236 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.047785 /$0.1108 .

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

A new SolarPower Europe report has found that new solar installations in 2023 grew by 87% year-on-year to bring the world's total solar-energy capacity to a whopping 1.6 TW. Solar energy is still ahead of other green-energy sources, partly due to low prices, and accounted for 78% of global green-energy installations last year, making it one of the world's primary sources of renewable energy. According to the report, new global solar installations in 2023 reached 447 GW compared to 239 GW the previous year. SolarPower Europe's annual Global Market Outlook for Solar Power 2024–2028 estimates that the world's total solar capacity could potentially reach 2 TW by the end of 2024. If there is enough energy-system flexibility, a substantial amount of stationary energy storage and funding, the report said, solar energy's yearly growth rate could hit 1 TW by the year 2028. According to SolarPower Europe, tripling the world's renewable-energy capacity as per COP28 will call for around $12 billion in global investments. As solar-energy capacity ramps up rapidly, the zero-emissions vehicles commercialized by companies such as Mullen Automotive Inc. (NASDAQ: MULN) could deliver even more benefits if those vehicles are charged using clean energy from the sun or other sources.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Wednesday's trading session at $2.48, up -4.6154%, on 1,667,325 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $2.3565 /$289.08 .

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced its entry into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 568,000 shares of common stock in a registered direct offering and warrants to purchase up to 568,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the "offering") at a combined purchase price of $2.45 per share. The warrants issued per the concurrent private placement will have an exercise price of $2.32 per share, exercisable immediately following the date of issuance, with a 5-year expiration from the initial exercise date. Subject to the satisfaction of customary conditions, the closing of the offering is expected to occur on or about June 27, 2024. The gross proceeds are expected to be approximately $1.39 million, from which the company intends to use the net for working capital and general corporate purposes.

To view the full press release, visit

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $1.84, up -35.2113%, on 1,540,478 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $1.61 /$6875.00 .

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave Quantum Inc. (NYSE: QBTS) ("D-Wave"), a leader in quantum computing systems, software and services, and the world's first commercial supplier of quantum computers, has been named as one of the finalists for the BC Tech Association's GameChanger Ambition award. The company has been recognized in the category of Technology Impact Awards ("TIAs").

According to the announcement, the GameChanger Ambition award recognizes companies that utilize technology to tackle big problems, specifically acknowledging game-changers that "aren't afraid to address big problems, lead from the front and use technology to build a better future." Award winners will be announced at the TIA gala in October 2024.

"This finalist nomination means a tremendous amount to the technology team in our British Columbia-based Quantum Engineering Center of Excellence," said D-Wave Quantum chief development officer Trevor Lanting in the press release. "We are making amazing strides to advance the science of quantum computing as well as develop six generations of quantum computing systems and are honored to receive this recognition. We are grateful to BC Tech for being a stalwart champion of innovation and for helping companies like D-Wave promote our talent around the world."

To view the full press release, visit

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer


With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service


D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Wednesday's trading session at $1.06, up -2.7523%, on 3,603,872 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.57 /$3.20 .

Recent News

SenesTech Inc. (NASDAQ: SNES)

The QualityStocks Daily Newsletter would like to spotlight SenesTech Inc. (NASDAQ: SNES).

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, today announced that its minimum-risk soft bait for the proactive control of rats, Evolve(TM), will be deployed in the U.S Virgin Islands as part of an international effort to control invasive species in environmentally sensitive areas. The Wild Ecology Group is administering this effort. SenesTech has developed and is in the process of commercializing a proprietary technology for managing animal pest populations, primarily rats, through fertility control. "The Wild Ecology Group sees Evolve as part of a long term, sustainable solution to invasive species proliferation and is being rolled out to over 60 islands in our care," said Nick Morrison of the Wild Ecology Group. "Ultimately, Evolve will be our ‘standard of care' as we assess our programs worldwide."

To view the full press release, visit

SenesTech Inc. (NASDAQ: SNES) is the rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats. The company’s technology provides an innovative and humane method for managing rat populations.

SenesTech is focused on developing effective solutions that are grounded in science and proven through research, all while providing value to people, communities and the environment. The company’s passion is to create a healthier world by better controlling rat pest populations. This aim is critical, as, if left unchecked, a breeding pair of rats and their descendants can produce up to 15,000 pups after just one year.

The company strives for clean cities, efficient businesses and happy households – with a product that was scientifically designed to be effective without killing rats. SenesTech is committed to the sustainable, humane treatment of animals, improving the quality of all human life and enhancing environmental stewardship through the global application of its effective solution in fertility control technology.

SenesTech is headquartered in Phoenix, Arizona.


SenesTech’s first product, ContraPest®, applies revolutionary technology to a global challenge that has persisted since the Middle Ages – the proliferation of rats in urban and agricultural settings. ContraPest® targets the reproductive capabilities of Norway and roof rats. As a highly palatable liquid, the formulation promotes sustained consumption, helping to reduce fertility in both male and female rats, bringing populations down and keeping them down.

The company’s flagship offering can be used as part of integrated pest management (IPM) programs – fitting seamlessly into all IPM programs – to help reduce reproduction and magnify the success of these protocols, or as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods.

In multiple, independent field deployments, ContraPest was shown to reduce rat activity over 90% when added to an existing IPM program.

ContraPest® is registered federally as a General Use Product.

Delivery Systems and New Products

In July 2023, SenesTech began to distribute a new delivery system for ContraPest®, the Isolate Bait System™. This new delivery system brings to market a simple design that enables more efficient deployment, incorporates an enhanced formulation of ContraPest® that is expected to provide improved performance of the fertility control bait in the field and is paired with a new bait station that is more space-efficient and economical.

The other delivery systems available for ContraPest include the Ultimate Bait System™, a tank and tray in a larger format for use with more severe infestations, and the Elevate Bait System™, a unique delivery system that targets above ground infestations, as with roof rats.

SenesTech, as of August 2023, is also in the final stages of releasing a soft bait formulation, which provides the unique attributes of proven fertility control in an industry-familiar format demanded by big box retailers, key e-commerce channels and leading industry pest management professionals.

Market Opportunity

According to SenesTech’s figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States. Rats also destroy 20% of the global stored food supply every year by consuming or contaminating it.

Rats are known to spread at least 35 diseases, globally posing a dangerous risk to public health and safety. Not only does this age-old problem persist despite extensive campaigns to eradicate it, but multiple sources have reported that post-COVID rat populations have boomed.

Poison-based control methods sicken rats, and they typically die slowly. An animal that eats a poisoned rat may also sicken or die. The global rodenticide market is projected to be worth $1.7 billion by 2026.

In one case study, results reported by the customer showed a $5,000 investment in ContraPest® saved more than $500,000 annually in reduced labor, loss and damage.

Management Team

Joel Fruendt is SenesTech’s President and CEO. He has 15 years of executive leadership in the vector and pest control industries as Vice President and General Manager of Clarke Environmental Inc., a leading vector and pest control products and services company. He has extensive expertise in the development and manufacturing of EPA-registered chemical control products, and the commercialization and sale of those products. He received the ‘Smart Leaders’ award from Smart Business Magazine and holds a bachelor’s degree in business from Illinois Wesleyan University.

Tom Chesterman is CFO at SenesTech. He has over 20 years of experience as the CFO of public companies in the life science, tech and telecommunications industries. Most recently, he was the Vice President and Treasurer of GCI, a telecommunications company. Previous to that, he was the CFO of life science companies Bio-Rad Laboratories, Aradigm and Bionovo. He has a bachelor’s degree from Harvard University and an MBA from the University of California at Davis.

Dan Palasky is Chief Technical Officer at SenesTech. Previously he held the title of Vice President of Research & Development at PLZ Corp., a manufacturer of chemical consumer products, serving as the technical expert for its entire product portfolio. He started his career with Camie-Campbell, Inc., as a chemist in the R&D department. Mr. Palasky received his bachelor’s degree in chemical engineering from the Missouri University of Science & Technology and his MBA in Project Management from Aspen University.

SenesTech Inc. (NASDAQ: SNES), closed Wednesday's trading session at $0.6295, up -0.8973551%, on 54,869 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.52 /$15.00 .

Recent News

Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF)

The QualityStocks Daily Newsletter would like to spotlight Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF) .

For a month now, gold miners' stocks have been falling, chipping away at traders' enthusiasm. This is usual for the metal around this period before it surges even higher, which means traders have the opportunity to add undervalued gold stocks to their portfolios before the metal's price increases. Up until mid-May, VanEck Gold Miners ETF performed strongly, increasing in price by more then 44% in under three months. Other stocks performed just as strongly, which increased overbuying. When the month ended, however, VanEck's ETF fell from its 200-day moving average of 1.25x to 1.09x. This means that overbuying has reduced, and sentiment now has shifted to apathy. American stock investors may have not yet jumped on the bandwagon, but central bankers and investors in China have already began purchasing these stocks and are far from done. Some expect that once the stock bubble on artificial intelligence companies stalls then bursts, investors will shift demand to the precious metal. Those who have diversified their tech-heavy portfolios to include gold may gain even more. The anticipated seasonal surge could favor those that have invested in gold stocks such as Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF) and other major extraction companies in the industry.

Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF) is a leading gold explorer in the Guiana Shield, South America. In early 2021, the Company announced an exciting new greenfield gold discovery at its Oko West project in Guyana, where, after 22 months of resource definition drilling, the Company has announced an initial Mineral Resource Estimate (MRE) containing 2.475 Moz of gold in Indicated resources at 1.84 g/t and 1.762 Moz of gold in inferred resources at 2.02 g/t contained within a pit shell outline. Preliminary metallurgy results performed by the company, consisting of 8 bottle roll tests obtained strong results, averaging just under 90% recoveries on average. The Company is continuing with additional development activities at Oko West, including environmental base line studies and additional metallurgical work relating to the delivery of a PEA by year end 2023. In addition, Reunion Gold is currently exploring several priority targets in the Oko West project area on which the company feels there is good potential to add additional resource ounces. This includes the opportunity to grow the initial mineral resource estimate (MRE) released on June 13, 2023, and to discover additional gold ounces at Oko West outside of the resource area.

The Guiana Shield remains one of the most prospective exploration locations globally for the discovery of world class orogenic gold deposits. The shield, including both Guyana and Surinam, contain large relatively underexplored greenstone belts, from which Reunion Gold expects many more significant gold discoveries could emerge in the coming years.

Oko West Project

Reunion Gold’s Oko West Project is a brand-new gold discovery in northwest Guyana located within the historical Oko gold district. Alluvial gold has been mined from the Oko district since the turn of the century, but very little primary gold has been mined or even explored for to the best of the company’s knowledge. The project comprises a prospecting license with an area of approximately 44 square kilometers and is 100% held by Reunion’s Guyanese subsidiary.

In 2020, Reunion Gold’s geochemical survey, trenching and initial 1000 m drill program discovered and confirmed the presence of gold mineralization in this Orogenic gold system. The gold occurs in the eastern edge of the project area, along a 6km long sheared contact between a granitoid intrusion and a meta volcanic-meta sedimentary rock package. The MRE is located within the Kairuni zone, which represents the northern most 1.9 km of the 6 km long contact.

“We are advancing our Oko West project along two tracks. The first is to advance the exploration programs outside of the Kairuni zone, aimed at outlining and discovering additional gold mineralization within our Prospecting License. On this front, I am very excited by the results from the initial Scout RC Geochem drill program that is defining new targets west of our Kairuni zone,” Rick Howes, President and CEO of Reunion Gold, stated in a recent news release. In addition to the targets west of the Kairuni zone, the company has also commenced exploration work on the southern ~ 4 km of the same sheared contact that hosts the Kairuni zone MRE. In addition, the company feels that the MRE marks the size of the Kairuni resource at a point in time and that there is good potential to continue to grow the resource. The MRE remains open at depth below the resource pit outline in the block 4 area and also to depth and along strike in the block 5 and 6 areas. In addition to the exploration programs, the second strategic track is to rapidly advance the Kairuni zone along the path to development. To that end the company is moving forward with the engineering and other studies, including more detailed metallurgical studies, that will support the release a PEA on the Kairuni zone by year end 2023 The company feels that the rapid advancement of development of Kairuni zone MRE, while in parallel continuing to explore for additional ounces on the project, is the best path to try and maximize shareholder value in the shortest period of time.


Guyana boasts a long history of mining gold, bauxite, diamonds and manganese. Still, the greenstone belts of the Guiana Shield remain relatively unexplored when compared to the analogous regions of the West African Shield (Birimian), which, according to geological evidence, was once connected to the Guiana Shield, forming a contiguous craton prior to the Mesozoic period.

Despite a historical lack of accessibility and low exploration intensity, several significant large-scale projects have emerged in the Guiana Shield, including Aurora, Oko West, Oko Main, Toroparu and Omai. Guyana is English speaking with a British based parliamentary and legal system and boasts the world’s fastest growing economy on the back of significant offshore oil discoveries by Exxon and its partners. It is expected that a significant amount of the revenues from oil production will be invested in improving the infrastructure, education and health care and agriculture within the country.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, called 2022 the “strongest year for gold demand in over a decade.” Annual gold demand jumped 18% YoY due to “colossal central bank purchases, aided by vigorous retail investor buying and slower ETF outflows.”

Despite this spike in demand, total annual gold supply increased by just 2% in 2022, halting two years of successive declines but failing to challenge 2018 highs. This supply-demand imbalance could provide a favorable market environment as Reunion Gold continues to advance drilling programs at its 100%-owned Oko West Project.

Management Team

Successful exploration and the discovery of significant deposits in any given region require immense amounts of local knowledge and experience. This is the principle around which Reunion Gold has built its management team. In total, the company’s leadership boasts over 225 years of combined experience in the Guiana Shield.

David Fennell is the Executive Chairman of Reunion Gold, a position he has held since the company’s inception in 2003. He has 40 years of experience in the mining industry. He received a law degree from the University of Alberta in 1979 and practiced law until he founded Golden Star Resources Ltd. in 1983. During his term as President and CEO, Golden Star became one of the largest and most successful exploration companies. While at Golden Star, he was instrumental in the discovery and development of the Omai Gold Mine in Guyana and the Gross Rosebel Mine in Suriname. In 1998, Mr. Fennell became Chairman and CEO of Hope Bay Gold Corporation. He held this position through the merger of Hope Bay and Miramar Mining Corporation and remained as Executive Vice-Chairman and Director for the combined entity until its takeover by Newmont Mining Corporation in 2008. Mr. Fennell is currently a member of the board of directors of G Mining Ventures Corp. and Sabina Gold & Silver Corp.

Rick Howes, P.Eng., is the company’s President and CEO. He is a seasoned mining executive with over 39 years of experience in the mining industry, most recently as CEO of Dundee Precious Metals. Mr. Howes has extensive operating, technical and project development experience in both underground and open pit mines throughout Canada and internationally. In 2009, Mr. Howes joined Dundee Precious Metals, where, as VP and General Manager, he led the transformation of the Chelopech Mine in Bulgaria to reach world-class levels of performance. He became COO in 2011 and oversaw several significant growth capital development projects, including the expansion of the Chelopech Mine, the upgrade and expansion of the Tsumeb Smelter in Namibia and the development of the greenfield Ada Tepe open pit gold mine in Bulgaria. He was appointed CEO in April 2013, leading Dundee’s transformation from a junior gold producer to a multi-asset mid-tier gold producer generating strong free cashflow and solid returns to shareholders. Mr. Howes has been recognized as a visionary leader in mining, organizational innovation and transformation and was recognized as the Outstanding Innovator of 2016 by the International Mining Technology Hall of Fame.

Alain Krushnisky is the CFO of Reunion Gold. He brings to the company years of experience in the mining sector, including 10 years with Cambior Inc. (now IAMGOLD) in capacities such as Vice-President and Controller. Since 2004, Mr. Krushnisky has been doing consulting work for various publicly listed exploration and mining companies. He graduated from the University of Ottawa in 1983 with a bachelor’s degree in commerce and is a Chartered Professional Accountant.

Justin van der Toorn is the company’s VP Exploration. He is an exploration geologist with 18 years’ experience in the minerals industry, leading and managing exploration teams from grassroots activities through to discovery and resource definition drilling. Mr. van der Toorn’s previous experience has been in a range of commodity and deposit styles, including extensive work in Carlin-style gold, low- and high-sulphidation epithermal, porphyry and orogenic gold systems. He holds an MSci degree in Geological Sciences from the Royal School of Mines, Imperial College London. He is registered as a Chartered Geologist (CGeol) of the Geological Society, and a European Geologist (EurGeol) by the European Federation of Geologists.

Doug Flegg is the company’s business Development advisor. Doug has over 35 years’ experience in mining and mining finance with senior positions in research, portfolio management and global equity sales. Previously, Mr. Flegg was Managing Director Global Mining Sales with BMO Capital Markets where he was involved in raising $35 billion in over 200 corporate financings. Since 2016 he has been providing business development, strategic, and financing advice to corporate mining clients. Mr. Flegg also has a B.Sc. in Geology, work experience as a geologist and an MBA from Queens University.

Reunion Gold Corp. (OTCQX: RGDFF), closed Wednesday's trading session at $0.49855, up -0.29%, on 59,559 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.24 /$0.50 .

Recent News

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF)

The QualityStocks Daily Newsletter would like to spotlightFathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF).

Fathom Nickel (CSE:FNI) (FSE: 6Q5) (OTCQB: FNICF) today announced the addition of the Friesen Lake property to its growing portfolio. The property encompasses three mineral dispositions acquired by staking directly through the Government of Saskatchewan's MARS portal. "In light of recent activity in the Albert Lake property area, we made the decision to stake three claims to cover the Friesen Lake Ni-Cu-Pt showing and acquire land that puts us adjacent to the Toppings Lake Cu-Ni showing," said Ian Fraser, CEO and VP Exploration. "Both showings are ultramafic-mafic hosted and have the potential to host significant magmatic nickel sulphide-styles of mineralization. Of significant interest to us is the platinum-palladium associated with the Friesen Lake showing. It is very intriguing to us that >1 g/t Pt-Pd occurs in historic surface trenching and that significant Pt-Pd has been confirmed in historic drilling at Friesen Lake. The recent Ramp Metals Inc. drill result announcement has brought a lot of attention to the area and, as the accompanying Figure 1 illustrates, a bit of a staking rush. We felt it was important for Fathom to secure these dispositions and cover these known Ni-Cu-Pd-Pt showings before the staking frenzy grabbed this land ahead of us. As first movers in the area, we believe we have the largest and most prospective land package this region has to offer, providing us incredible exploration optionality."

To view the full press release, visit

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) is a Canadian natural resource development and exploration company that targets high-grade nickel sulfide discoveries for use in the rapidly growing global electric vehicle (EV) market. The company has a portfolio of two high-quality exploration projects located in the prolific Trans Hudson Corridor in Saskatchewan.

Led by a management team with more than 100 years of combined mining and exploration experience, Fathom believes in a continuing bright outlook for nickel and its increasing use in the manufacturing of batteries needed for energy storage in the high-growth renewable energy and EV industries. The company’s modern approach to exploration has yielded significant new nickel discoveries.

Fathom is headquartered in Calgary, Alberta.


The Albert Lake Project

The Albert Lake Project comprises 90,460 hectares of lands located in north-central Saskatchewan, with over 80,000 hectares currently unexplored. The project is host to the historic Rottenstone Mine, a high-grade, open pit nickel sulfide past producer that was active from 1965 to 1969 and yielded ~26,000 tonnes of 3.3% Ni, 1.8% Cu, and >9 g/t Pd-Pt+Au.

The geological setting of the Albert Lake Project is within the Trans Hudson Orogeny (Corridor), which is host to numerous world-class nickel mining camps including the Thompson Nickel Belt (currently operating with more than 5 billion pounds of nickel produced since 1959), Lynn Lake (past producer) and Raglan Nickel Belt (currently operating with more than 39,000 tons of nickel produced in 2020).

The project is fully permitted. Exploration plans for 2024 include drilling a high-priority target located approximately 2km south of the historic Rottenstone Mine along with drilling other high-priority targets. Additional soil geochemistry, surface geophysical programs and geological mapping and prospecting will be performed during the summer field season.

The Gochager Lake Project

The Gochager Lake Project in northern Saskatchewan, also in the prolific Trans Hudson Corridor, was recently expanded through the addition of the contiguous Watt’s Lake property and direct staking, bringing its total land area to 22,620 hectares.

The Gochager Lake property is host to a historic resource defined by drilling in 1966-1967 consisting of 4.2 M tons grading 0.29% Ni and 0.08% Cu. Recent drilling by Fathom has defined multiple very robust off-hole borehole electromagnetic (BHEM) responses in eight of nine holes drilled in 2023 and three historic drill holes probed. There is very strong evidence of multiple, high-grade nickel-copper-cobalt steeply oriented chutes within the historic Gochager Lake Deposit.

Prior to Fathom exploration in 2023 and since 1970, exploration at the property has been limited to small drill programs in 1989-1990 and 2018. Exploration plans for 2024 include expanded surface geophysical programs, drilling and continued BHEM surveys to expand tons and increase the grade of the historic Gochager Lake deposit. Summer exploration will consist of soil geochemistry, mapping, prospecting and additional surface geophysical programs focused on identifying other Gochager-like deposits within the current land package.

Market Opportunity

Nickel plays a crucial role in clean energy technologies, and that is expected to cause demand to well outstrip supply for the foreseeable future.

With an annual market value of around $35 billion, nickel demand is projected to rise due to its intensive use in lithium-ion batteries used to power EVs. However, new discoveries of nickel sulfide deposits (currently the most reliable source for battery-grade class 1 nickel) have been rare, which could constrain class 1 nickel supply in the coming years.

According to Deloitte’s global EV forecast, total EV sales will grow from 2.5 million in 2020 to 11.2 million in 2025, reaching 31.1 million by 2030 and representing approximately 32% of the total market share for new car sales. Over the next 10 years, the EV market is projected to see a CAGR of 29%, with increased demand for nickel expected to be comparable.

Management Team

Fathom Nickel has assembled a best-in-class leadership team consisting of highly qualified industry professionals with deep knowledge and understanding of the mineral exploration industry and capital markets.

Ian Fraser, P.Geo., is CEO, VP Exploration and Co-Founder of Fathom Nickel. He has more than 35 years of experience in mineral exploration, as well as managing and implementing exploration projects in Canada and internationally. His experience includes resource interpretation and development of the Casa Berardi Gold Mine and Komis Gold Mine, as well as the Cisneros Gold Mine in Colombia.

Doug Porter, CPA, CA, CBV, is President, CFO and Director of Fathom Nickel. He is a senior financial and accounting executive with specific emphasis in resource company management. His career includes positions with Elan Coal Ltd., Altitude Resources Ltd. and StimWrx Oilfield Services Ltd.

Fathom Nickel Inc. (OTCQB: FNICF), closed Wednesday's trading session at $0.0379, up -9.7619%, on 30,270 volume with 00 trades. The average volume for the last 3 months is 130,350 and the stock's 52-week low/high is $0.0222 /$0.2634 .

Recent News

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

"A myriad of opportunities has emerged for (cannabis) investors, entrepreneurs and enthusiasts worldwide," reports Newsweek

MedCana's agreement to begin exporting CBD buds to Switzerland appears to be particularly timely

The company noted that this new collaboration marks a "significant milestone" in the company's expansion into the European market

Interest in cannabis is growing globally, and savvy companies operating in the cannabis space, such as Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ), are working to strengthen their positions. Most recently, MedCana announced a new strategic partnership between one of its subsidiaries and a prominent Colombian company to begin export of its first crop of CBD buds to Switzerland within the next six months (

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.


MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Wednesday's trading session at $0.025, up -9.0909%, on 25,000 volume with 00 trades. The average volume for the last 3 months is 3,834 and the stock's 52-week low/high is $0.000001 /$0.09 .

Recent News

Golden Triangle Ventures Inc. (OTC: GTVH)

The QualityStocks Daily Newsletter would like to spotlight Golden Triangle Ventures Inc. (GTVH).

GTVH enters pivotal agreement with largest note holder, T&K Zarro LLC

CEO notes that agreement demonstrates "our commitment to strengthening our capital structure and delivering tangible value to our shareholders"

The agreement is a "testament" to the company's strategic foresight and dedication to fostering a robust and scalable business model

Golden Triangle Ventures (OTC: GTVH) continues momentum as the company announces strategic steps in its commitment to solidifying its capital structure, expanding its business operations and enhancing shareholder value. Most recently, the company revealed a pivotal agreement with T&K Zarro LLC, GTVH's largest note holder (

Golden Triangle Ventures Inc. (OTC: GTVH) is a multifaceted consulting company pursuing ventures in the health, entertainment and technology industries, with many additional projects being developed that provide synergistic values to these divisions. The company aims to purchase, acquire and/or joint venture with established entities that management can help assist and develop into unique opportunities.

Additionally, GTVH provides a professional corporate representation service to different companies in these sectors while consulting on a variety of business development objectives. The goods and services represented are driven by innovators who have passion and commitment to these marketplaces.

The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent these three sectors in which the company aims to do business.

Health Division – Global Health Services

Global Health Services is a wholly owned subsidiary of Golden Triangle Ventures (operating under its Health Division). Dedicated to the promotion of well-being and natural wellness, the company currently does business in the industrial hemp/CBD industry. Additionally, the company has a vision to promote, market and generate sales for a myriad of products and services which include a full retail line of high-end, all-natural health, wellness and beauty products.

To help achieve this vision, Global Health Services is in the process of further developing an extensive online portal that will support the multiple verticals under the company and provide a one-stop-shop for all of the company’s products and services. Moreover, to support overarching business goals, senior management tirelessly works on acquiring and building an array of profitable assets and projects.

Entertainment Division – Lavish Entertainment

Lavish Entertainment (EpicRaves) is a wholly owned subsidiary of Golden Triangle Ventures under its Entertainment Division. Operating out of Las Vegas, Nevada, the company started doing business in 2017 and was established with a vision of becoming a nationally recognized concert production company. The company currently has more than 30,000 national followers and nearly 100 team members who have helped the company successfully organize some of the most exciting Electronic Dance Music concerts in Las Vegas.

Lavish Entertainment is currently doing business as EpicRaves, which will eventually become a wholly owned subsidiary of Lavish Entertainment as the company expands its business into a variety of other forms of entertainment. The company is currently building a unique virtual reality platform to help expand on its live events, and it is working to acquire a 68,000 sq. ft. event center with a vision to develop one of the most advanced event centers in the world.

Technology Division – HyFrontier Technology

HyFrontier Technologies is a wholly owned subsidiary of Golden Triangle Ventures under its Technology Division. The company owns a patent-pending process and device technology called HyGrO, which is a molecular hydrogen and oxygen delivery system for agriculture. Golden Triangle Ventures is assisting the company in commercializing the HyGrO unit for farm and home use in markets across the globe. HyFrontier Technologies has a mission to improve global crop production efficiency by producing hydrogen and oxygen directly in the water stream.

This technology can be used on any species of plant life in nearly any grow medium. Additionally, the system can be retrofitted to wellheads for large-scale agricultural projects, indoor grow operations and small farms or utilized for a multitude of residential home and garden applications. In-house testing has shown evidence that hydrogen is capable of increasing crop yields by up to 25% and, in many circumstances, a much higher amount. Larger root systems and better overall plant health were also observed by watering plants with the HyGrO unit. Universities and multiple third-party testing facilities are currently working to validate the HyGrO technology, and all preliminary results are extremely positive.

To push the development and commercialization of the technology, management is now in the process of moving the company headquarters from Colorado to Florida, which will transition its operations into a 7,800 sq. ft. state-of-the-art manufacturing facility. The company recently executed a three-year lease with an option to purchase the entire 24,000 sq. ft. building, which will help the business in achieving its ultimate goal of commercializing this technology to the world.

Food & Wine Division – Napa Wine Brands

Napa Wine Brands is a wholly owned subsidiary of Golden Triangle Ventures which is a synergistic business with a mission of providing a world-class portfolio of unique brands birthed from Napa Valley and Sonoma Valley in the heart of California’s Wine Country.

The company has a commitment to manufacture and distribute specialty wines, foods and unique items while tapping into an array of hidden markets in the food and beverage industry. With extensive resources and award-winning products, Napa Wine Brands aims to develop some of the most desirable products in today’s market. Originated by some of the most profound experts in Napa Valley, the company’s vision is to broaden the horizon of a traditional food and wine company by creating a platform different than anything seen in the Northern Hemisphere.

Napa Wine Brands has an array of fully developed products and services that provide value to the other divisions under Golden Triangle Ventures. The company is now preparing the launch of several brands, products and services that are market-ready and will immediately turn into cash-positive businesses. Golden Triangle Ventures will provide a full support system and assist management of Napa Wine Brands in growing this company into another fun, exciting and profitable division of Golden Triangle Ventures.

Recent Updates

  • On May 26, 2021, Golden Triangle announced its acquisition of The Lodge Winery & Olive Oil Co. under the company’s Napa Wine Brands subsidiary. The Lodge Winery & Olive Oil Co. is an established wine brand that produces award-winning wines, olive oils and wine vinegars. “Our marketing team is now ready to launch an in-depth program focused on driving our products into big box stores, smaller retail outlets, online platforms and many other avenues,” Steffan Dalsgaard, CEO of Golden Triangle, stated in a news release announcing the acquisition. “We are working directly with [Napa Wine Brands CEO] Arron [Johnson] and his team to grow their bulk inventory and launch all of these products for the world to enjoy.”
  • On May 20, 2021, Golden Triangle announced its entry into a letter of intent to acquire Sonder Fulfillment LLC, a leader in the industrial hemp and CBD space that is dedicated to driving forward the most powerful and efficacious cannabinoid products in the world. “Over the past two years, our operating partners have compiled a team of the best minds in the industrial hemp industry to create a totally vertical operation from seed to shelf,” Joshua Weaver, CEO of Sonder Fulfillment, stated in a news release announcing the LOI. “This acquisition by Golden Triangle Ventures will fully capitalize our operations and allow us to further expand our product lines and enter into new markets across the globe.”
  • On May 19, 2021, Golden Triangle announced the execution of a formal agreement with Robert “Bo” DuBose to purchase the remaining 49% of HyFrontier Technologies Inc., giving Golden Triangle 100% ownership of the technology company. “This acquisition has been something that Bo and I have been working towards for quite some time and we are both incredibly happy to have this executed,” Dalsgaard stated in a news release announcing the acquisition. “We knew that completing this agreement would show the world that we are both fully committed to our shareholders and the brilliant future of this revolutionary company.”
  • On May 12, 2021, Golden Triangle announced its acquisition of a top tier, professional sound system and formed a partnership with SuperKollider Sound LLC to provide a strategic benefit to the company’s entertainment division under Lavish Entertainment Inc. “We are very excited to acquire this unbelievable sound system,” Dalsgaard stated in a news release announcing the acquisition. “Hennessey Sound Design has always been one of my favorite systems on the market, and the team at SuperKollider Sound are true professionals in this space.”

Management Team

Steffan Dalsgaard is the Founder & Executive Chairman of Golden Triangle. He has a background in business development, with over a decade of experience representing and consulting with dozens of private and public companies. Mr. Dalsgaard consults with companies on all of their corporate objectives while providing a professional and corporate face to their organizations. He has built a strong reputation in the public relations industry and has a mission to work with emerging growth companies that are positioned to become significant businesses in their respective fields.

Robert DuBose is the company’s Chief Innovations Officer & Director and the CEO of HyFrontier Technologies Inc. Mr. DuBose is responsible for the success of the HyGrO product in the agricultural market. His experience in the design and production of hydrogen equipment goes back more than a decade, including PEMFC technologies since 2009 with his company, Aquafuel Inc. Mr. DuBose was raised in the farming and machine shop business, where he learned firsthand how much work and love goes into a successful crop, as well as how elements, which are out of the farmers control, can have adverse effects on finances. His belief that being able to deliver a solution to increase growth, yield, health, stamina of crops and profitability for farmers would be a win-win for all led him to create the HyGrO product.

Stuart Seim is the Chief Development Officer & Director of Golden Triangle. He began his career as an associate professor at the University of Manitoba in the field of outdoor and environmental education after receiving his master’s degree and completing advanced educational studies. Coming from a family with an extensive financial background, Mr. Seim became a stockbroker for major regional financial firm Robert W. Baird. In a short time, he became the Branch Manager for Baird in Minneapolis, Minnesota, while also serving as a Managing Director for Baird. During this time, Mr. Seim also served on the board of an industrial hearing company, which he helped to launch as a new company (The TK Group). Mr. Seim currently resides in Colorado, where he is an advisor to several organizations.

Golden Triangle Ventures Inc. (GTVH), closed Friday's trading session at $10.83, up 4.4359%, on 81,689 volume with 697 trades. The average volume for the last 3 months is 269,609 and the stock's 52-week low/high is $2.33999991/$20.0783996.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.